VANCOUVER, Feb. 21, 2013 /CNW/ - Abattis Bioceuticals Corp. (the
"Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces the
engagement of Triangle Consultants to represent Abattis at the various
government levels across Canada.
Mr. Mike Withrow, Chief Executive Officer on behalf of the Company,
stated, "We are pleased to have a team of seasoned and experienced
professionals who are Triangle Consultants working in government
regulations and policies on our behalf." Mr. Withrow went on to state,
"We are confident in the capabilities that Triangle brings to Abattis
and believe they will achieve all of the milestones we have established
Mr. Norm Vocino, President of Triangle Consultants, stated, "We are
pleased to be working with Abattis in helping them attain their future
goals and objectives", continued Mr. Vocino, "We look forward to
putting our unique and strategic business approach as well as the
expertise and resources of Triangle Consultants, into this exciting
About Triangle Consultants
Triangle consultants is a boutique consulting firm specializing in
providing valuable advice, strategies and direction for a wide variety
of private and public companies and organizations. Our approach
enables our clients to unlock the full potential of their
opportunities. Through our extensive experience and network, we are
able to quickly assess our client's needs and develop a unique and
strategic path forward.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and bio-similar
compounds for use in Pharmaceuticals, Nutraceutical, Cosmetic and
Animal Nutrition markets. The company also has a deep pipeline of
proprietary products ready for sale in high growth areas of Functional
Foods and Supplements business. For more information, visit the
Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
Neither the CNSX Exchange nor its regulations services accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Abattis Bioceuticals Corp.
For further information: